Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors

References

• Davies DR. The structure and function of the aspartic proteinases. Ann Rev Biophys BioPhys Chem 1990;19:189–215.
   PubMedGoogle Scholar
• Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. Curr Pharm Des 2007;13:271–285.
   PubMed Web of Science ®Google Scholar
• Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;27:157–162.
   PubMed Web of Science ®Google Scholar
• Kay J, Dunn BM. Substrate specificity and inhibitors of aspartic proteinases. Scand J Clin Lab Invest 1992;52:23–30.
   Web of Science ®Google Scholar
• Zurcher M, Gottschalk T, Meyer S, Bur D, Deiderich F. Exploring the flap pocket of the antimalarial target plasmepsin II: The ‘55% rule’ applied to enzymes. Chem Med Chem 2008;3:237–240.
   Web of Science ®Google Scholar
• De Clercq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002;1:13–25.
   PubMed Web of Science ®Google Scholar
• Jedinak A, Maliar T. Inhibitors of proteases as anticancer drugs. Neoplasma 2005;52:185–192.
   PubMed Web of Science ®Google Scholar
• Azim MK, Zaidi ZH. Molecular modeling of human procathepsin E: analysis of salt-bridge interactions between propeptide and enzyme segment. Biochem Biophys Res Commun 1999;264:825–832.
   PubMed Web of Science ®Google Scholar
• Ersmark K, Samuelsson B, Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev 2006;26:626–666.
   PubMed Web of Science ®Google Scholar
• Cooper JD, Russell C, Mitchison HM. Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis. Biochem Biophys Acta 2006;1762:873–889.
   PubMed Web of Science ®Google Scholar
• Liu J, Istvan ES, Gluzman IY, Gross J, Goldberg DE. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci USA 2006;103:8840–8845.
   PubMed Web of Science ®Google Scholar
• Bjelic S, Nervall M, Gutierrez-de-Teran H, Ersmark K, Hallberg A, Aqvist J. Computational inhibitor design against malaria plasmepsins. Cell Mol Life Sci 2007;64:2285–2305.
   PubMed Web of Science ®Google Scholar
• Bjelic S, Nervall M, Gutierrez-de-Teran H, Ersmark K, Hallberg A, Aqvist J. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J Med Chem 1999;42:1428–1440.
   PubMed Web of Science ®Google Scholar
• Dahlgren A, Kvarnstrom I, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. New inhibitors of the malaria aspartyl proteases plasmepsin I and II. Bioorg Med Chem 2003;11:3423–3437.
   PubMed Web of Science ®Google Scholar
• Corminboeuf O, Dunet G, Hafsi M, Grimont J, Grisostomi C, Meyer S, Binkert C, Bur D, Jones A, Prade L, Brun R, Boss C. Inhibitors of plasmepsin II-potential antimalarial agents. Bioorg Med Chem Lett 2006;16:6194–6199.
   PubMed Web of Science ®Google Scholar
• Muthas D, Noteberg D, Sabnis YA, Hamelink E, Vrang L, Samuelsson B, Karlen A, Hallberg A. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II. Bioorg Med Chem 2005;13:5371–5390.
   PubMed Web of Science ®Google Scholar
• Hidaka K, Kimura T, Ruben AJ, Uemura T, Kamiya M, Kiso A, Okamoto T, Tsuchiya Y, Hayashi Y, Freire E, Kiso Y. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem 2008;16:10049–10060.
   PubMed Web of Science ®Google Scholar
• Jiang S, Prigge ST, Wei L, Gao Y-E, Hudson TH, Gerena L, Dame JB, Kyle DE. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob Agents Chemother 2001;45:2577–2584.
   PubMed Web of Science ®Google Scholar
• Azim MK, Ahmed W, Khan IA, Rao NA, Khan KM. Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Bioorg Med Chem Lett 2008;18:3011–3015.
   PubMed Web of Science ®Google Scholar
• Blum A, Bottcher J, Sammet B, Luksch T, Heine A, Klebe G, Deiderich WE, Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors. Bioorg Med Chem 2008;16:8574–8586.
   PubMed Web of Science ®Google Scholar
• Luksch T, Chan NS, Brass S, Sotriffer CA, Klebe G, Deitderich WE. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. ChemMedChem 2008;3:1323–1336.
   PubMed Web of Science ®Google Scholar
• Ciugureanu C, Ungureanu M, Grosu G. The antibacterial action of new hydrazide derivatives. Rev Med Chir 1993;97:433–437.
   Google Scholar
• Waisser K, Houngbedji N, Odlerrova Z, Thiel W, Mayer R. Antitubercular agents. Thiohydrazides, potential antitubercular agents. Pharmazie 1990;45:141–142.
   PubMed Web of Science ®Google Scholar
• Khan MK, Rasheed M, Zia-Ullah Hayat, S, Kaukab F, Choudhary MI, Atta-ur-Rahman Perveen, S. Synthesis and in vitro leishmanicidal activity of some hydrazides and their analogues. Bioorg Med Chem 2003;11:1381–1387.
   PubMed Web of Science ®Google Scholar
• Cardellini M, Claudi F, Grifantini M, Gulini U, Martelli S. Indolizine derivatives with biological activity I: N’-substituted hydrazides of indolizine-2-carboxylic acid. J Pharm Sci 1977;66:259–262.
   PubMed Web of Science ®Google Scholar
• Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261:470–489.
   PubMed Web of Science ®Google Scholar
• Silva AM, Lee AY, Gulnik SV, Maier P, Collins J, Bhat TN, Collins PJ, Cachau RE, Luker KE, Gluzman IY, Francis SE, Oksman A, Goldberg DE, Erickson JW. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc Natl Acad Sci USA 1996;93:10034–10039.
   PubMed Web of Science ®Google Scholar
• Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC II, Cachau RE, Collins J, Silva AM, Erickson JW. Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design. Proc Natl Acad Sci USA 1993;90:6796–6800.
   PubMed Web of Science ®Google Scholar
• Bohm H-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput-Aided Mol Design 1994;8:243–256.
   PubMed Web of Science ®Google Scholar
• Teran-de-Gutierrez H, Nervall M, Ersmark K, Liu P, Janka LK, Dunn B, Hallberg A, Advist J. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum. Biochemistry 2006;45:10529–10541.
   PubMed Web of Science ®Google Scholar